Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATP1A1 | P05023 | 1/20 | 0.43 |
| ▸ | ATP1B1 | P05026 | 1/20 | 0.43 |
| ▸ | ATP1A3 | P13637 | 1/20 | 0.43 |
| ▸ | ATP1B2 | P14415 | 1/20 | 0.43 |
| ▸ | ATP1A2 | P50993 | 1/20 | 0.43 |
| ▸ | ATP1B3 | P54709 | 1/20 | 0.43 |
| ▸ | FXYD2 | P54710 | 1/20 | 0.43 |
| ▸ | ATP1A4 | Q13733 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.43 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.40 |
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.40 |
| ▸ | TLR4 | O00206 | 1/20 | 0.40 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.40 |
| ▸ | SCN5A | Q14524 | 3/20 | 0.40 |
| ▸ | MGAT2 | Q10469 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1742825 | 0.86 | TLR9 (0.46) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 | |
| SCHEMBL1742877 | 0.84 | ACACB (0.49) | SLC6A7MAPTGPR119OGAACACB | |
| SCHEMBL1742670 | 0.83 | OGA (0.49) | EPHX2MAP4K1SLC6A7OGA | |
| SCHEMBL1742764 | 0.81 | OGA (0.46) | SLC6A7TLR4TLR8OGAACACB | |
| SCHEMBL1742772 | 0.78 | OGA (0.44) | SLC6A7MAPTTLR4TLR8OGA | |
| SCHEMBL12159783 | 0.78 | FYN (0.46) | MAPTTLR4TLR8OGA | |
| SCHEMBL19531522 | 0.78 | ALDH1A1 (0.56) | EPHX2MAP4K1MAPT | |
| SCHEMBL1744211 | 0.76 | OGA (0.42) | MAPTTLR4TLR8OGA | |
| SCHEMBL1743089 | 0.76 | CYP1A2 (0.41) | MAP4K1MAPTTLR4TLR8OGA | |
| SCHEMBL9986179 | 0.75 | PTPN11 (0.39) | MAPTGPR119TLR4TLR8OGA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2233470-B1 | Histamine H3 receptor antagonists | HIGH POINT PHARMACEUTICALS LLC (US) | 2011-12-07 | — | — | EP | claimed |
| EP-2233470-A1 | Histamine H3 receptor antagonists | High Point Pharmaceuticals, LLC (US) | 2010-09-29 | — | — | EP | claimed |
| US-8846677-B2 | Medicaments | HIGH POINT PHARMACEUTICALS, LLC (US) | 2014-09-30 | — | — | US | disclosed |
| US-8846677-B2 | Medicaments | HIGH POINT PHARMACEUTICALS, LLC (US) | 2014-09-30 | — | — | US | disclosed |
| US-8846677-B2 | Medicaments | HIGH POINT PHARMACEUTICALS, LLC (US) | 2014-09-30 | — | — | US | disclosed |
| US-8501739-B2 | Medicaments | HIGH POINT PHARMACEUTICALS, LLC (US) | 2013-08-06 | — | — | US | disclosed |
| US-8501739-B2 | Medicaments | HIGH POINT PHARMACEUTICALS, LLC (US) | 2013-08-06 | — | — | US | disclosed |
| US-8501739-B2 | Medicaments | HIGH POINT PHARMACEUTICALS, LLC (US) | 2013-08-06 | — | — | US | disclosed |
| US-20120232078-A1 | Novel Medicaments | HIGH POINT PHARMACEUTICALS, LLC (US) | 2012-09-13 | — | — | US | disclosed |
| US-20120232078-A1 | Novel Medicaments | HIGH POINT PHARMACEUTICALS, LLC (US) | 2012-09-13 | — | — | US | disclosed |
| US-20120232078-A1 | Novel Medicaments | HIGH POINT PHARMACEUTICALS, LLC (US) | 2012-09-13 | — | — | US | disclosed |
| EP-2386554-A1 | Compounds active at the histamine H3 receptor | High Point Pharmaceuticals, LLC (US) | 2011-11-16 | — | — | EP | disclosed |
| EP-2386554-A1 | Compounds active at the histamine H3 receptor | High Point Pharmaceuticals, LLC (US) | 2011-11-16 | — | — | EP | disclosed |
| EP-2233470-A1 | Histamine H3 receptor antagonists | High Point Pharmaceuticals, LLC (US) | 2010-09-29 | — | — | EP | disclosed |
| US-20090312309-A1 | Novel Medicaments | HIGH POINT PHARMACEUTICALS, LLC (US) | 2009-12-17 | — | — | US | disclosed |
| US-20090312309-A1 | Novel Medicaments | HIGH POINT PHARMACEUTICALS, LLC (US) | 2009-12-17 | — | — | US | disclosed |
| US-20090312309-A1 | Novel Medicaments | HIGH POINT PHARMACEUTICALS, LLC (US) | 2009-12-17 | — | — | US | disclosed |
| EP-1902028-A2 | HISTAMINE H3 RECEPTOR ANTAGONISTS | Novo Nordisk A/S (DK) | 2008-03-26 | — | — | EP | disclosed |
| WO-2007003604-A2 | HISTS1MINE H3 RECEPTOR ANTAGONISTS | NOVO NORDISK A/S (DK) | 2007-01-11 | — | — | WO | disclosed |
| WO-2007003604-A2 | HISTS1MINE H3 RECEPTOR ANTAGONISTS | NOVO NORDISK A/S (DK) | 2007-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232078-A1 | Novel Medicaments | HRH3, HRH4, HRH1 | ATP1A1 2107/4885ATP1B1 2164/4885ATP1A3 1415/4885 |
| US-20090312309-A1 | Novel Medicaments | HRH3, HRH4, HRH1 | ATP1A1 2107/4885ATP1B1 2164/4885ATP1A3 1415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.